RxDoctor Payments Data

Naeem Akhtar, MD

Psychiatry · Lexington, KYNPI 1629248588

Payments from drug & device makers

$1,081in general payments, 2019–2025

Across 33 payments — averaging $32.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$427
  • Alkermes, Inc.$172
  • AstraZeneca$110
  • Lundbeck LLC$90
  • Johnson & Johnson$77
  • Otsuka America Pharmaceutical, Inc.$61
  • plus $144 from 5 others

What the payments were for

  • Travel & lodging$42740%
  • Food & beverage$65460%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,081 in reported general payments places this provider in the 65th percentile of 348 psychiatry providers in Kentucky.

See all psychiatry providers in Kentucky

Medicare billing

Part B allowed, 2024
$24,074
Medicare patients
58
Services billed
266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate90$275,910
Abilify MaintenaAripiprazole40$101,010
Invega TrinzaPaliperidone Palmitate11$75,620
AustedoDeutetrabenazine12$55,637
AristadaAripiprazole Lauroxil17$49,423
VraylarCariprazine Hcl24$33,918
Olanzapine192$7,321
Paliperidone ErPaliperidone30$7,280
Divalproex Sodium ErDivalproex Sodium81$7,185
Quetiapine Fumarate ErQuetiapine Fumarate45$6,477
Aripiprazole204$6,380
Clozapine52$5,910
Divalproex Sodium85$5,131
Buspirone Hcl287$4,350
Lurasidone Hcl28$4,151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$77$351,531101 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$61$101,01040 claims
Teva Pharmaceuticals USA, Inc.Austedo$17$55,63712 claims
Alkermes, Inc.Aristada$172$49,42317 claims
AbbVieVraylar$12$33,91824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 348 psychiatry providers in Kentucky.

Other psychiatry in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →